| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD003610.PUB3 |
| P932 | PMC publication ID | 6483534 |
| P50 | author | Christian Gluud | Q26265142 |
| Asbjørn Hróbjartsson | Q30004128 | ||
| Janus C Jakobsen | Q41279147 | ||
| P2093 | author name string | Christian Gluud | |
| Janus C Jakobsen | |||
| Maria Skoog | |||
| Naqash J Sethi | |||
| Sanam Safi | |||
| Steven Kwasi Korang | |||
| P2860 | cites work | What Is an Antibiotic or an Antibiotic Substance? | Q22305716 |
| Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods | Q24288962 | ||
| Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 | ||
| Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 | ||
| Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report | Q24674636 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis | Q26783046 | ||
| Pathophysiology of coronary artery disease leading to acute coronary syndromes | Q26822054 | ||
| Multiple Infectious Agents and the Origins of Atherosclerotic Coronary Artery Disease | Q27330093 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Association of Chlamydia pneumoniae Infection With Atherosclerotic Plaque Formation | Q28833753 | ||
| A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints | Q29614902 | ||
| Inflammation and atherosclerosis | Q29615203 | ||
| Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses | Q29619185 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology | Q29619792 | ||
| Progress and challenges in translating the biology of atherosclerosis | Q29619982 | ||
| Meta-analyses involving cross-over trials: methodological issues | Q29620304 | ||
| Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis | Q38786058 | ||
| False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review | Q38926363 | ||
| Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial | Q39053506 | ||
| The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk | Q41126565 | ||
| Relation of Helicobacter pylori infection and coronary heart disease | Q41333642 | ||
| Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden | Q41734547 | ||
| Prevalence of periodontal pathogens in coronary atherosclerotic plaque of patients undergoing coronary artery bypass graft surgery | Q42234805 | ||
| Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease | Q43240149 | ||
| Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? | Q43707230 | ||
| Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death | Q44054655 | ||
| Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs | Q46450288 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials | Q47192223 | ||
| Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators | Q50866437 | ||
| Methods for combining randomized clinical trials: strengths and limitations | Q52599212 | ||
| 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart | Q52956605 | ||
| Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. | Q55041689 | ||
| AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update | Q57072671 | ||
| Population attributable burden of Helicobacter pylori-related gastric cancer, coronary heart disease, and ischemic stroke in China | Q30244173 | ||
| Bioactive microbial metabolites | Q31157729 | ||
| Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses | Q33372680 | ||
| Estimating required information size by quantifying diversity in random-effects model meta-analyses. | Q33521365 | ||
| Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease | Q33646625 | ||
| Optimal use of modern antibiotics: emerging trends | Q33728584 | ||
| Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies | Q33776566 | ||
| H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. | Q33866718 | ||
| Infections, inflammation, and the risk of coronary heart disease | Q33887538 | ||
| Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses | Q33910496 | ||
| Chronic Oral Infection with Porphyromonas gingivalis Accelerates Atheroma Formation by Shifting the Lipid Profile | Q33916483 | ||
| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres | Q34046881 | ||
| The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study | Q34058272 | ||
| Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? | Q34174166 | ||
| Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation | Q34193483 | ||
| Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial | Q34248742 | ||
| High serum antibody levels to Porphyromonas gingivalis predict myocardial infarction | Q34379307 | ||
| Epidemiological studies of CHD and the evolution of preventive cardiology | Q34411784 | ||
| Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials | Q34422834 | ||
| Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. | Q34503313 | ||
| Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association | Q34505315 | ||
| 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q34657387 | ||
| Macrolide antibiotics: binding site, mechanism of action, resistance | Q35100800 | ||
| Immunomodulatory effects of quinolones | Q35143094 | ||
| C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis | Q35182277 | ||
| Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. | Q35709736 | ||
| Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics | Q36072425 | ||
| Trial Sequential Analysis in systematic reviews with meta-analysis | Q36298738 | ||
| Tetracyclines: nonantibiotic properties and their clinical implications | Q36380200 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis | Q36510758 | ||
| Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation | Q36582329 | ||
| C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study | Q36598316 | ||
| The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews | Q36721160 | ||
| Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men | Q36832346 | ||
| Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses | Q37138228 | ||
| The association between current Helicobacter pylori infection and coronary artery disease | Q37205516 | ||
| Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis | Q37346172 | ||
| Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability | Q37361893 | ||
| Inflammation in atherosclerosis: transition from theory to practice | Q37672113 | ||
| Antimicrobial agents-associated with QT interval prolongation | Q37704457 | ||
| Lack of strong association of Chlamydia pneumoniae and atherosclerosis in a Jordanian population | Q37836191 | ||
| Chlamydia Pneumoniae and Immunoinflammatory Reactions in an Unstable Atherosclerotic Plaque in Humans | Q37840244 | ||
| Association between Chlamydophila pneumoniae infection and risk of coronary heart disease for Japanese: the JPHC study | Q37844894 | ||
| Infections as a stimulus for coronary occlusion, obstruction, or acute coronary syndromes | Q37854268 | ||
| Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis | Q37860076 | ||
| Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries | Q37860141 | ||
| Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome | Q37865020 | ||
| Azithromycin for the secondary prevention of coronary events | Q37865023 | ||
| Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice | Q37869175 | ||
| Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results? | Q37869786 | ||
| Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice | Q37870991 | ||
| Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease. | Q37871182 | ||
| Predisposition to atherosclerosis by infections: role of endothelial dysfunction | Q37871635 | ||
| Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis | Q37872578 | ||
| Prospective study of pathogen burden and risk of myocardial infarction or death | Q37875116 | ||
| Atherosclerosis in apoE knockout mice infected with multiple pathogens | Q37875166 | ||
| Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study | Q37878753 | ||
| Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd | Q37878769 | ||
| Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease | Q37878785 | ||
| Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction | Q37878896 | ||
| Chronic infections and coronary heart disease: is there a link? | Q37882245 | ||
| Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction | Q37882420 | ||
| Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease | Q37884972 | ||
| Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease | Q37891247 | ||
| In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). | Q37897794 | ||
| Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction | Q37899465 | ||
| The epidemiology of coronary heart disease | Q38209293 | ||
| A Meta-Analysis of the Association between Helicobacter pylori Infection and Risk of Coronary Heart Disease from Published Prospective Studies | Q38495577 | ||
| Systematic Reviews of Anesthesiologic Interventions Reported as Statistically Significant: Problems with Power, Precision, and Type 1 Error Protection | Q38637092 | ||
| P433 | issue | 7 | |
| P921 | main subject | antibiotic | Q12187 |
| coronary artery disease | Q844935 | ||
| P577 | publication date | 2017-07-18 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Antibiotics for secondary prevention of coronary heart disease | |
| P478 | volume | 2017 |
Search more.